Evidence map›Paper›PMID 31451973›Full record

ArticleEuropean radiology2020

Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18-24-month follow-ups.

Grace Hyun J Kim, Stephan S Weigt, John A Belperio, Matthew S Brown, Yu Shi, Joshua H Lai, Jonathan G Goldin

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.American journal of respiratory and critical care medicine · 2024
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2025
    Article
  9. Article
  10. Article
  11. Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. HyperpolarizedRadiology · 2022
    Article
  16. Article
  17. Towards Treatable Traits for Pulmonary Fibrosis.Journal of personalized medicine · 2022
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Grace Hyun J KimDavid Geffen School of Medicine, Radiological Science, UCLA, 924 Westwood Blvd. Ste 650, Box 957319, Los Angeles, CA, 90095-7319, USA. gracekim@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-1225-3489
Stephan S WeigtUCLA Med-Pul Critical Care, Los Angeles, USA.
John A BelperioUCLA Med-Pul Critical Care, Los Angeles, USA.
Matthew S BrownDavid Geffen School of Medicine, Radiological Science, UCLA, 924 Westwood Blvd. Ste 650, Box 957319, Los Angeles, CA, 90095-7319, USA.
Yu ShiFielding School of Public Health, Biostatistics, Computer Vision and Imaging Biomarkers, UCLA, 924 Westwood Blvd. Ste 650, Box 957319, Los Angeles, CA, 90095-7319, USA.
Joshua H LaiDavid Geffen School of Medicine, Radiological Science, UCLA, 924 Westwood Blvd. Ste 650, Box 957319, Los Angeles, CA, 90095-7319, USA.
Jonathan G GoldinDavid Geffen School of Medicine, Radiological Science, UCLA, 924 Westwood Blvd. Ste 650, Box 957319, Los Angeles, CA, 90095-7319, USA.
University of California, Los Angeles · USFielding Graduate University · US

Funding

Prediction of IPF Progression Using Imaging PatternsR21HL123477 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KIM, GRACE HYUN JUNG · 2015 to 2016
$215k
NHLBI NIH HHS R21 HL123477NIH-NHLBI NIH-NHLBI R21HL123477-01A1
6 · The paper itself

Abstract

objectiveHigh-resolution computed tomography (HRCT) plays an indispensable role in the diagnosis of idiopathic pulmonary fibrosis (IPF). Due to unpredictability in progression and the short median survival of 2-5 years, it is critical to delineate the patients with rapid progression. The aim is to evaluate the predictability of IPF progression using the early quantitative changes.

methodsAutomated texture-based quantitative lung fibrosis (QLF) was calculated from the anonymized HRCT. Two datasets were collected retrospectively: (1) a pilot study of 35 subjects with three sequential scans (baseline and 6 and 12 months) to obtain a threshold, where visual assessments were stable at 6 months but worsened at 12 months; (2) 157 independent subjects to test the threshold. Landmark Cox regressions were used to compare the progression-free survival (PFS) defined by pulmonary function using the threshold from the early changes in QLF. C-indexes were reported as estimations of the concordance of prediction.

resultsA threshold of 4% QLF change at 6 months corresponded to the mean change that worsened on HRCT visually at 12 months from the pilot study. Using the threshold, significant differences were found in the independent dataset (hazard ratio (HZ) = 5.92, p = 0.001 by Cox model, C-index = 0.71 at the most severe lobe; and HZ = 3.22, p = 0.012, C-index = 0.68 in the whole lung). Median PFS was 11.9 months for subjects with ≥ 4% changes, whereas median PFS was greater than 18 months for subjects with < 4% changes at the most severe lobe.

conclusionEarly structural changes on HRCT using a quantitative score can predict progression in lung function. KEY POINTS: • Changes on HRCT using quantitative texture-based scores can play a pivotal role for providing information and an aid tool for timely management decision for patients with IPF. • Quantitative changes on HRCT of 4% or more, which matched 6-month prior changes with visual assessment of worsening, can play a pivotal role for providing prediction of clinical progression by 3-5 folds higher in the next incidence, compared with those of subjects with less than 4% changes. • Early structural changes of 4% or more in a paired HRCT scans derived by quantitative scores can predict the progression in lung function in 1-2 years in subjects with IPF, which is critical information for timely management decision for subjects with IPF where the median survival is 2 to 5 years.

Indexed as

AgedDisease ProgressionFemaleFollow-Up StudiesHumansIdiopathic Pulmonary FibrosisLungMalePilot ProjectsPredictive Value of TestsProportional Hazards ModelsReproducibility of ResultsRetrospective StudiesTomography, X-Ray ComputedIdiopathic pulmonary fibrosisInterstitial lung diseasePredictionProgressiveQuantitative evaluation

Identifiers

PMID31451973
OpenAlexW2970194878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.